Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer (Q39911616)

15 September 2017

Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer (English)

1 reference

15 September 2017

1 reference

Katsuhiro Okuda

1

1 reference

15 September 2017

Hidefumi Sasaki

2

1 reference

15 September 2017

Haruhiro Yukiue

3

1 reference

15 September 2017

Motoki Yano

4

1 reference

15 September 2017

Yoshitaka Fujii

5

1 reference

15 September 2017

1 November 2008

1 reference

15 September 2017

1 reference

15 September 2017

99

1 reference

15 September 2017

11

1 reference

15 September 2017

2280-2285

1 reference

Revisions in the International System for Staging Lung Cancer

15 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00916.X

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00916.X

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00916.X

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00916.X

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00916.X

Novel mutations of the MET proto-oncogene in papillary renal carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00916.X

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00916.X

TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00916.X

Scatter-factor and semaphorin receptors: cell signalling for invasive growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00916.X

Met, metastasis, motility and more

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00916.X

A broad-spectrum human lung fibroblast-derived mitogen is a variant of hepatocyte growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00916.X

Scatter factor is a fibroblast-derived modulator of epithelial cell mobility

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00916.X

Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00916.X

Scatter factor induces blood vessel formation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00916.X

Class III beta-tubulin isotype: a key cytoskeletal protein at the crossroads of developmental neurobiology and tumor neuropathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00916.X

An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00916.X

Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00916.X

EGFR and erbB2 mutation status in Japanese lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00916.X

Characterizing the cancer genome in lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00916.X

Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00916.X

Frequent amplification of the c-met gene in scirrhous type stomach cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00916.X

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00916.X

MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00916.X

ErbB3 mRNA expression correlated with specific clinicopathologic features of Japanese lung cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00916.X

Somatic mutations lead to an oncogenic deletion of met in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00916.X

10.1111/J.1349-7006.2008.00916.X

21 January 2018

Identifiers

DOI

1 reference

15 September 2017

1 reference